Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 14

1.

A potential therapeutic peptide-based neutralizer that potently inhibits Shiga toxin 2 in vitro and in vivo.

Li T, Tu W, Liu Y, Zhou P, Cai K, Li Z, Liu X, Ning N, Huang J, Wang S, Huang J, Wang H.

Sci Rep. 2016 Feb 23;6:21837. doi: 10.1038/srep21837.

2.

The global aHUS registry: methodology and initial patient characteristics.

Licht C, Ardissino G, Ariceta G, Cohen D, Cole JA, Gasteyger C, Greenbaum LA, Johnson S, Ogawa M, Schaefer F, Vande Walle J, Frémeaux-Bacchi V.

BMC Nephrol. 2015 Dec 10;16:207. doi: 10.1186/s12882-015-0195-1.

3.

Retrograde Trafficking Inhibitor of Shiga Toxins Reduces Morbidity and Mortality of Mice Infected with Enterohemorrhagic Escherichia coli.

Secher T, Shima A, Hinsinger K, Cintrat JC, Johannes L, Barbier J, Gillet D, Oswald E.

Antimicrob Agents Chemother. 2015 Aug;59(8):5010-3. doi: 10.1128/AAC.00455-15. Epub 2015 May 18.

4.

Management of hemolytic uremic syndrome.

Kavanagh D, Raman S, Sheerin NS.

F1000Prime Rep. 2014 Dec 1;6:119. doi: 10.12703/P6-119. eCollection 2014. Review.

5.

A non-invasive laboratory panel as a diagnostic and prognostic biomarker for thrombotic microangiopathy: development and application in a Chinese cohort study.

Zhang T, Chen H, Liang S, Chen D, Zheng C, Zeng C, Zhang H, Liu Z.

PLoS One. 2014 Nov 5;9(11):e111992. doi: 10.1371/journal.pone.0111992. eCollection 2014.

6.

A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS).

Rathbone J, Kaltenthaler E, Richards A, Tappenden P, Bessey A, Cantrell A.

BMJ Open. 2013 Nov 4;3(11):e003573. doi: 10.1136/bmjopen-2013-003573.

7.

Symptoms and clinical course of EHEC O104 infection in hospitalized patients: a prospective single center study.

Ullrich S, Bremer P, Neumann-Grutzeck C, Otto H, Rüther C, von Seydewitz CU, Meyer GP, Ahmadi-Simab K, Röther J, Hogan B, Schwenk W, Fischbach R, Caselitz J, Puttfarcken J, Huggett S, Tiedeken P, Pober J, Kirkiles-Smith NC, Hagenmüller F.

PLoS One. 2013;8(2):e55278. doi: 10.1371/journal.pone.0055278. Epub 2013 Feb 27.

8.

Shiga toxin in enterohemorrhagic E.coli: regulation and novel anti-virulence strategies.

Pacheco AR, Sperandio V.

Front Cell Infect Microbiol. 2012 Jun 7;2:81. doi: 10.3389/fcimb.2012.00081. eCollection 2012. Review.

9.

Thrombotic microangiopathies.

Radhi M, Carpenter SL.

ISRN Hematol. 2012;2012:310596. doi: 10.5402/2012/310596. Epub 2012 Jul 25.

10.

Thrombotic microangiopathy and associated renal disorders.

Barbour T, Johnson S, Cohney S, Hughes P.

Nephrol Dial Transplant. 2012 Jul;27(7):2673-85. doi: 10.1093/ndt/gfs279. Review.

11.

Attending rounds: microangiopathic hemolytic anemia with renal insufficiency.

Clark WF, Hildebrand A.

Clin J Am Soc Nephrol. 2012 Feb;7(2):342-7. doi: 10.2215/CJN.07230711. Epub 2011 Dec 22.

12.

Malignant hypertension complicated by acute renal failure.

Li X, Zhang W, Ren H, Pan X, Chen N.

BMJ Case Rep. 2009;2009. pii: bcr10.2008.1116. doi: 10.1136/bcr.10.2008.1116. Epub 2009 Jun 15.

13.

46-year-old man with fatigue and brown urine.

Mao MA, Hoyt JR, Nyman MA.

Mayo Clin Proc. 2011 Mar;86(3):e16-9. doi: 10.4065/mcp.2010.0197. No abstract available.

14.

Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome.

Nathanson S, Kwon T, Elmaleh M, Charbit M, Launay EA, Harambat J, Brun M, Ranchin B, Bandin F, Cloarec S, Bourdat-Michel G, Piètrement C, Champion G, Ulinski T, Deschênes G.

Clin J Am Soc Nephrol. 2010 Jul;5(7):1218-28. doi: 10.2215/CJN.08921209. Epub 2010 May 24.

Items per page

Supplemental Content

Write to the Help Desk